Share Prices & Company Research

Stockbroking

4d Pharma Ord 0.25p

Current Price 120.60p Bid 120.00p Ask 125.00p Change 16.67%
Last Updated: 18/04/2019 17:20. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

4d pharma plc was founded in February 2014. It is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has completed a Phase I study in Irritable Bowel Syndrome and has completed dosing in a Phase I study in Paediatric Crohn's Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence one additional clinical study in 2018 and a further three in 2019.

Financial Highlights Year Ended 31/12/2017

Turnover
£0.00m
Operating Profit
£-24.35m
Dividend Yield
0.00
Dividend Per Share
0.00
Dividend Cover
0.00
P/E Ratio
-3.20

Key Personnel

Duncan Joseph Peyton
Chief Executive Officer
Alexander James Stevenson
Chief Scientific Officer
David Robert Norwood
Non-Executive Chairman
Thomas Engelen
Non-Executive Director

Stock Details

EPIC
DDDD
ISIN
GB00BJL5BR07
Shares in Issue
65,493,842
Market cap
£65.82m

Analyst Views (0)

Strong Buy
 
0.00%
Buy
 
0.00%
Hold
 
0.00%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
122.50p
Bid Price
120.00p
Ask Price
125.00p
Volume
42169
Change Today
17.50p
% Change Today
16.67%
Open
109.91p
Previous Close
122.50p
Intraday High
130.00p
Intraday Low
108.93p
52 Week High
250.00p
52 Week Low
77.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

4d Pharma  Ord 0.25p Intra-day Chart

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2017
31 Dec 2016
Tangible Assets
5.2
3.9
Intangible Assets & Goodwill
14.7
14.3
Investments & Other Non-Current Assets
0.1
0.0
Total Non-Current Assets
19.9
18.2
Inventory
0.3
0.2
Trade & Receivables
3.2
2.7
Cash & Receivables
11.9
28.7
Other Current Assets & Assets Held for Resale
42.4
43.4
Total Assets
77.7
93.2

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2017
31 Dec 2016
Short Term Liabilities
5.0
4.9
Long Term Liabilities
3.0
1.7
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
8.0
6.7

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2017
31 Dec 2016
Net Assets
69.8
86.5

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2017
31 Dec 2016
Share Capital
0.2
0.2
Minority Interests
0.0
0.0
Retained Earnings
-39.9
-19.4
Share Premium Account
108.3
105.9
Other Equity
1.2
-0.2
Total Equity
69.8
86.5

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2017
31 Dec 2016
Cashflow from Operating Activities
-17.2
-13.5
Cashflow Before Financing
-16.8
26.5
Increase / Decrease in Cash
-16.8
26.9

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2017
31 Dec 2016
Turnover
0.0
0.0
Cost of Sales
0.0
0.0
Gross Profit
0.0
0.0
Operating Profit
-24.4
-12.3
Pre-Tax Profit
-24.0
-11.7
Profit / Loss for the Year
-20.5
-9.9
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.